DrugAdjunctive line

Leukotriene receptor antagonists

CysLT1 receptor blockade (montelukast)

Response rate
Modest in AERD subtype
Onset
Weeks
Route
Oral 10mg daily
Line
Adjunctive
IgM effect
Minimal
Evidence level
amber

Evidence summary

Most effective in AERD subtype where cysteinyl leukotriene overproduction drives disease. Montelukast can reduce polyp size and improve symptoms in this subset. Limited efficacy in non-AERD CRSwNP.

Sources (1)

T5Fokkens WJ et al. (2020) EPOS/EUFOREA 2020 treatment algorithm for CRSwNPDOI ↗
Leukotriene receptor antagonists — Drug Profile | Kipine